Why Is Inflammation Disease-Focused Celldex Therapeutics Stock Trading Higher Today?
Celldex Therapeutics Inc (NASDAQ: CLDX) released topline results from its Phase 2 trial of barzolvolimab in patients with moderate to severe chronic spontaneous urticaria (CSU) refractory to antihistamines, including patients who received prior biologics.
CSU is characterized by the occurrence of hives or wheals for six weeks or longer ...
Disclaimer: The views, recommendations, and opinions expressed in this content belong solely to the third-party experts. This site was not involved in the writing and production of this article.